(Q39568919)

English

Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.

scientific article published on 18 June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Maria Santacana

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Xavier Matias-Guiu Guia

14

object named as

Xavier Matias-Guiu

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Andree Yeramian

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Xavier Dolcet

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Leandre Abal

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Sara Moreno

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Ramón Egido

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Josep M Casanova

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Ramón Vilella

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Antonio Llombart-Cussac

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

language of work or name

0 references

publication date

18 June 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

International Journal of Cancer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

130

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

967-978

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21445974%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Molecular pathogenesis of cutaneous melanocytic neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

KIT as a therapeutic target in melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Understanding melanoma signaling networks as the basis for molecular targeted therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Locus of fragility in robust breast cancer system

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Mitogen-activated protein kinase pathways

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Phase II trial of imatinib mesylate in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26096

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39568919&oldid=1772069240"